Is Neomycin Ototoxic? Hearing Loss Risks and Signs

Neomycin is one of the most cochleotoxic aminoglycoside antibiotics in clinical use, meaning it can damage the sensory cells responsible for hearing and cause permanent hearing loss. Among the aminoglycoside family, neomycin stands out as particularly dangerous to the inner ear, which is why systemic (injected) use has been largely abandoned. But the drug still appears in topical ear drops, oral preparations, and over-the-counter wound ointments, and the risk picture changes dramatically depending on how it enters the body and who is using it.

How Neomycin Damages the Inner Ear

Aminoglycoside antibiotics work by binding to bacterial ribosomes and disrupting protein synthesis, which is how they kill bacteria. The problem is that the sensory hair cells in the inner ear have structures similar enough to bacterial targets that aminoglycosides can accumulate there and cause harm. Neomycin generates free radicals inside these hair cells, and the resulting oxidative stress triggers a chain of events that leads to cell death through apoptosis.

Once those hair cells are destroyed, they do not regenerate in humans. That makes the hearing loss permanent. Laboratory research has shown that the damage centers on reactive oxygen species (ROS) building up inside the cells, overwhelming the cells’ natural repair systems and activating programmed cell death pathways.¹ Neomycin is classified as primarily cochleotoxic, meaning it preferentially damages the hearing portion of the inner ear rather than the vestibular (balance) portion.² Temporal bone studies in humans have confirmed that neomycin does not cause loss of vestibular hair cells, which distinguishes it from aminoglycosides like gentamicin and streptomycin that predominantly affect balance.³

This distinction matters practically. If you develop ototoxicity from gentamicin, the main complaint is often dizziness or unsteadiness. With neomycin, the primary concern is hearing loss, typically starting at high frequencies before spreading to the range of everyday speech.

Routes of Exposure and Why They Matter

The risk of neomycin-induced hearing loss depends enormously on how the drug gets into your body. When neomycin was given by injection decades ago, the ototoxicity risk was severe enough that parenteral use was essentially discontinued. Today, most people encounter neomycin through one of three routes: topical ear drops, oral tablets taken to sterilize the gut before surgery, or skin ointments applied to wounds.

Oral neomycin is poorly absorbed from a healthy gut, which led to a long-standing assumption that swallowed neomycin is safe for the ears. For most people it is. But ototoxicity from oral neomycin has been documented, particularly in patients with kidney problems or inflammation in the gastrointestinal tract, both of which increase how much drug gets absorbed into the bloodstream.⁴ These cases are uncommon, but they undermine the idea that oral neomycin is categorically harmless to hearing.

Topical application to the skin, as in over-the-counter antibiotic ointments, carries minimal ototoxic risk because very little drug enters the bloodstream through intact skin. Ear drops are a different story entirely, and the risk hinges on whether the eardrum is intact.

The Eardrum Factor

When someone has an ear infection or a tympanostomy tube (ear tube), there is often an opening in the tympanic membrane. That opening creates a pathway for topical ear drops to reach the middle ear and potentially the inner ear, where hair cells are exposed directly to the drug. This is the scenario that concerns clinicians most.

A large retrospective study involving over 134,000 children treated with either neomycin or fluoroquinolone ear drops examined sensorineural hearing loss rates in kids who had non-intact tympanic membranes. For children who received two prescriptions of neomycin ear drops, the adjusted risk of sensorineural hearing loss was about 45% higher compared to those receiving fluoroquinolone drops.⁵ A single prescription did not show a statistically significant increase, and three or more prescriptions produced a hazard ratio that was elevated but had wide confidence intervals, making the estimate less certain. The pattern suggests a dose-related risk, but the evidence is not clean-cut, partly because children receiving multiple prescriptions often had more severe underlying ear disease.

Clinical practice guidelines for acute otitis externa explicitly state that when a patient has a tympanostomy tube or known perforation of the tympanic membrane, clinicians should prescribe a nonototoxic topical preparation rather than aminoglycoside-containing drops.⁶ This guideline reflects the precautionary principle rather than overwhelming proof of harm: the animal data on aminoglycoside ear drops and cochlear damage is strong, while human data remains limited and of variable quality.⁷

Who Faces the Highest Risk

Several factors stack the deck against certain patients. Understanding them helps explain why some people tolerate neomycin without problems while others suffer lasting hearing damage.

Kidney Impairment

Aminoglycosides are cleared through the kidneys. When kidney function is impaired, the drug lingers longer in the bloodstream at higher concentrations, giving it more time to accumulate in the inner ear. Renal impairment is one of the best-established risk factors for aminoglycoside ototoxicity across the entire drug class.⁴ This is relevant even for oral neomycin: a patient with chronic kidney disease who takes oral neomycin for bowel preparation absorbs the same small percentage as anyone else, but clears it far more slowly.

Concurrent Medications

The combination of aminoglycoside antibiotics with loop diuretics (drugs like furosemide, often given for heart failure or severe edema) produces a synergistic ototoxic effect, meaning the damage is greater than you would expect from either drug alone.⁸ Loop diuretics are themselves mildly ototoxic, and they appear to increase the permeability of the inner ear barrier, allowing more aminoglycoside to reach the hair cells. Patients receiving both drugs simultaneously need closer monitoring.

Mitochondrial DNA Mutations

Some people carry specific inherited mutations in their mitochondrial DNA that make them dramatically more susceptible to aminoglycoside-induced hearing loss. The most well-known of these is the m.1555A>G mutation in the 12S ribosomal RNA gene. This mutation causes human mitochondrial ribosomes to more closely resemble bacterial ribosomes, which is exactly the target aminoglycosides are designed to attack.⁹ As a result, the drug essentially treats the patient’s own inner ear cells more like bacteria.

Prior to recent reports, the m.1555A>G mutation was thought to cause hearing loss in 100% of exposed individuals who receive aminoglycosides.¹⁰ That assumption has been challenged by at least one documented case of a child with the mutation who maintained normal hearing despite repeated aminoglycoside exposure, suggesting the penetrance may not be absolute. Still, the risk is extremely high, and genetic testing before aminoglycoside use has been advocated in some clinical settings, though it is far from routine. A related mutation, m.1494C>T, carries a similar mechanism. Both are inherited maternally through mitochondrial DNA.

Laboratory work has shown that cells carrying the A1555G mutation exhibit decreased growth rates when exposed to high concentrations of neomycin specifically, compared to cells without the mutation, confirming a direct interaction between neomycin and the mutated ribosomal target.¹¹

Recognizing the Early Signs

Neomycin-related hearing loss typically begins in the high-frequency range, above the pitches used in normal conversation. This means you can lose a significant amount of hearing before you notice anything wrong in daily life. The first clue is often difficulty hearing consonant sounds like “s,” “f,” or “th,” or trouble following conversation in noisy environments. Tinnitus, a persistent ringing or buzzing in the ears, can be an early warning sign of aminoglycoside-induced cochlear damage and sometimes appears before measurable hearing loss on a standard audiogram.

Standard hearing tests cover frequencies up to about 8,000 Hz, but aminoglycoside damage often starts above that range. Extended high-frequency audiometry, which tests up to 16,000 or 20,000 Hz, can catch changes earlier. A study of pediatric cystic fibrosis patients who had extensive aminoglycoside exposure found that in those with the heaviest exposure, about one in five showed clear ototoxicity, with average high-frequency thresholds elevated by roughly 50 decibels and measurable reductions in otoacoustic emissions.¹² That study involved multiple aminoglycosides rather than neomycin specifically, but the underlying cochlear damage mechanism is shared across the class.

Because the damage is irreversible, the rationale for monitoring is to catch changes early enough to stop the drug before hearing loss reaches the speech-frequency range. For patients receiving systemic aminoglycosides in a hospital setting, serial audiometry is standard practice. For patients using neomycin-containing ear drops at home, formal monitoring rarely happens, which is one reason why the true incidence of topical neomycin ototoxicity in humans remains uncertain.

Children and Repeated Ear Drop Prescriptions

Children are the population most likely to receive neomycin-containing ear drops, because ear infections and ear tube placements are overwhelmingly pediatric problems. The large study of over 134,000 children mentioned earlier found that a single neomycin prescription did not significantly increase the risk of sensorineural hearing loss, but two prescriptions raised the risk by about 45% compared to fluoroquinolone drops.⁵ This is particularly concerning because hearing loss in young children can affect speech and language development in ways that are difficult to reverse later.

The complication in interpreting pediatric data is that children who need multiple courses of ear drops typically have more severe or recurrent ear disease, which itself can cause hearing problems. The study adjusted for several known risk factors, but residual confounding is difficult to eliminate entirely. Still, the finding has contributed to a clinical shift: many pediatric ear-nose-throat specialists now default to fluoroquinolone drops when the eardrum is not intact, viewing neomycin-containing preparations as an unnecessary gamble when safer alternatives exist.

What Clinical Guidelines Recommend

The American Academy of Otolaryngology’s clinical practice guideline for acute otitis externa specifically calls out the need for nonototoxic preparations when the tympanic membrane is not intact.⁶ In practice, this means fluoroquinolone-based drops, which have no demonstrated cochleotoxicity. When the eardrum is confirmed to be intact, neomycin-containing drops are generally considered safe for external ear infections, because the drug cannot reach the inner ear through a closed barrier.

The tension in clinical practice comes from uncertainty. A physician treating a child with drainage from an ear tube often cannot directly visualize the eardrum through the discharge. Using neomycin drops in that scenario means gambling that the drug will not penetrate to the inner ear. The guideline’s position is straightforward: when in doubt, choose the nonototoxic option. This has been a slow shift, partly because neomycin-polymyxin B-hydrocortisone drops are cheaper and have decades of clinical familiarity behind them.

Neomycin Allergy and Ear Treatment Complications

A separate but frequently overlapping problem with topical neomycin is allergic contact dermatitis. Neomycin is one of the most common causes of allergic contact sensitization among topical antibiotics, and the sensitization was first documented in a patient being treated for otitis externa.¹³ The allergy typically presents as a worsening of the condition being treated rather than a classic allergic rash, which makes it easy to mistake for a failing treatment. A patient using neomycin ear drops whose ear gets progressively more inflamed and painful may be having an allergic reaction rather than a treatment failure, but the instinct is often to continue the drops or increase the dose.

This matters for ototoxicity because the allergic inflammation can compromise the mucosal barrier in the ear, potentially increasing the absorption of the drug through damaged tissue. It also leads to prolonged use, since the clinician and patient keep applying the offending agent. Anyone with a known neomycin allergy should avoid all formulations containing it, including common triple-antibiotic ointments used on skin wounds.

Research Into Protecting Hair Cells

Because aminoglycoside ototoxicity centers on oxidative stress and free-radical damage, researchers have explored antioxidants and other compounds that might shield hair cells during drug exposure. Cell-culture studies have shown that vitamin C can protect auditory hair cells from neomycin-induced death by reducing reactive oxygen species and blocking the signaling pathways that trigger apoptosis.¹⁴ Another compound, paeoniflorin (a plant-derived molecule found in peony root), has shown similar protective effects in laboratory and animal models, reducing hair cell injury and attenuating hearing loss caused by neomycin.¹⁵

The research on autophagy has added another layer. In laboratory cell models, the cells’ natural autophagy process, a kind of internal recycling system, appears to suppress the accumulation of damaging free radicals and inhibit the cell death program triggered by neomycin.¹ Boosting autophagy could theoretically offer another route to protection, though this remains firmly in the preclinical phase.

None of these approaches has reached the point of a proven clinical intervention. No pill or ear drop exists yet that you can take alongside neomycin to reliably prevent hearing damage. The most effective current strategy remains avoiding unnecessary neomycin exposure, choosing alternative antibiotics when the risk profile is unfavorable, and monitoring hearing when aminoglycoside use is unavoidable.

Why Neomycin Remains in Use

Given all of this, you might wonder why neomycin has not simply been replaced. Part of the answer is cost: neomycin-containing ear drops and ointments are significantly cheaper than fluoroquinolone alternatives, and in many healthcare systems, cost drives prescribing habits. Part of the answer is inertia. Clinicians who trained using neomycin-polymyxin B formulations are comfortable with them and may view the ototoxicity risk as theoretical, especially when used short-term on an intact eardrum. And part of the answer is that for certain applications, the alternatives are not clearly better. In bowel preparation before colorectal surgery, oral neomycin combined with erythromycin remains a widely used regimen, and the ototoxicity risk in patients with normal kidneys and a healthy gut lining is genuinely low.

The shift away from neomycin ear drops has been gradual and uneven. In academic medical centers and pediatric specialty practices, fluoroquinolone drops are now the default for anything involving a non-intact eardrum. In primary care and urgent care settings, older neomycin-containing formulations still get prescribed regularly. If you are a patient or parent being given ear drops containing neomycin, asking whether the eardrum is intact is the single most useful question to raise with your clinician.